Onofri, Agnese
Iannone, Luigi Francesco
Granato, Antonio
Garascia, Gabriele
Bartole, Luca
Manganotti, Paolo
Vollono, Catello
Romozzi, Marina
Sottani, Costanza
Calabresi, Paolo
Tassorelli, Cristina
Sances, Grazia
Allena, Marta
De Icco, Roberto
De Cesaris, Francesco
Burgalassi, Andrea
Chiarugi, Alberto
Baraldi, Carlo
Guerzoni, Simona
Prudenzano, Maria Pia
Fallacara, Adriana
Albanese, Maria
Rainero, Innocenzo
Coppola, Gianluca
Casalena, Alfonsina
Mampreso, Edoardo
Pistoia, Francesca
Sarchielli, Paola
Morson, Marisa
Sacco, Simona
Geppetti, Pierangelo
Ornello, Raffaele http://orcid.org/0000-0001-9501-4031
,
Funding for this research was provided by:
Università degli Studi dell’Aquila
Article History
Received: 19 February 2023
Accepted: 14 March 2023
First Online: 20 March 2023
Declarations
:
: The Local Ethics Committee of Florence University—Comitato Etico Regionale della Regione Toscana—approved the study as a promoter center with code 14591_oss. The study was conducted according to the guidelines of the Declaration of Helsinki. Informed consent was obtained from all subjects involved in the study.
: Not applicable.
: SS reports consultant, advisory board, or speaker fees from Abbott, Allergan, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Medscape, Medtronic, Novartis, StarMed, Teva, and Uriach. RO reports speaker fees from Eli Lilly, Novartis, and Teva, support for attending meetings or travel from Novartis and Teva, advisory board fees from Eli Lilly, and nonfinancial support from Allergan and Novartis. PG received personal fees from Allergan, Eli Lilly, Novartis, Amgen, and TEVA; and grants from Amgen, TEVA, Eli Lilly, Allergan, and Chiesi; and is Scientific Advisory Board, Endosome Therapeutics; and founding scientist of FloNext srl, Spinoff of the University of Florence. FDC received personal fees from TEVA, Eli Lilly, and Novartis. LFI received speaker/advisory board fees from Eli Lilly and meeting/travel support by Lundbeck. GS reports advisory board, or speaker fees from Eli Lilly, Lundbeck, Novartis, and Teva and meeting/travel support by TEVA. RDI received speaker fees from Eli Lilly and TEVA. CT reports consultant, advisory board, or speaker fees from Allergan/AbbVie, Dompé, Eli Lilly, Pfizer, Medscape, Lundbeck, and Teva. CV reports speaker fees and support for attending meetings or travel from Eli Lilly. SG received honoraria and fees from Allergan/AbbVie, Eli Lilly, Teva, Novartis, and Lundbeck. CB received honoraria and fees from Allergan/AbbVie, Eli Lilly, Teva, Novartis, and Lundbeck.MPP received consultant, advisory board, or speaker fees from Allergan/AbbVie, Almirall, Bruno Farmaceutici, Eli Lilly, Fidia, Lundbeck, Novartis, Teva, and Valeas, and support for attending meetings from Allergan/AbbVie, Almirall, Bruno Farmaceutici, Eli Lilly, Idorsia, Lundbeck, Novartis, and Teva. AF received speaker fee from Eli Lilly and support for attending meetings from Lilly and Teva. IR reports speaker fees and support for attending meetings or travel from Eli Lilly, Teva, and Novartis. The other authors report that they have no competing interests.